How it works
Binds G-actin and promotes actin polymerisation, which drives cell migration into damaged tissue. It also stimulates endothelial cell differentiation and new capillary growth, and downregulates inflammatory cytokines.
Structure: 7 amino acids (actin-binding domain of Tβ4)
Reported benefits
- Improved cell migration and wound closure in animal studies
- Reported flexibility gains and reduced muscle spasm
- Systemic action rather than site-specific, unlike BPC-157
Practical considerations
- Frequently stacked with BPC-157 in anecdotal recovery protocols
- Human data is limited to Tβ4 trials in dry-eye and cardiac injury
- Prohibited by WADA at all times
Side effects and risks
- Fatigue or head-rush after dosing
- Injection-site reaction
- Theoretical tumour-growth concern given angiogenic activity
Dosing overview
Loading phase of 2–5 mg twice weekly for 4–6 weeks, then a lower maintenance dose
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Research references
- Goldstein et al., 2012 — Thymosin β4 in tissue repair
- Malinda et al., 1999 — Tβ4 accelerates wound healing